Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: A 52-Week International, Multi-centre, Randomized, Parallel-group, Double-blind, Active-controlled, Phase III Study With a 52-Week Extension Period to Evaluate the Safety and Efficacy of Saxagliptin in Combination With Metformin Compared With Sulphonylurea in Combination With Metformin in Adult Patients With Type 2 Diabetes Who Have Inadequate Glycaemic Control on Metformin Therapy Alone.
Brief Summary: Saxagliptin is a new investigational medication being developed for treatment of type 2 diabetes. This study is designed to assess the efficacy and tolerability of saxagliptin in addition to metformin and compare to sulphonylurea in addition with metformin.


Options:
A: Arm Label: linagliptin; Type: EXPERIMENTAL; Interventions: Drug: linagliptin, Drug: glimepiride placebo | Arm Label: glimepiride 1-4 mg QD; Type: ACTIVE_COMPARATOR; Interventions: Drug: glimepiride, Drug: linagliptin placebo | Intervention Type: DRUG; Name: linagliptin; Assigned to Arm(s): linagliptin | Intervention Type: DRUG; Name: glimepiride; Assigned to Arm(s): glimepiride 1-4 mg QD | Intervention Type: DRUG; Name: linagliptin placebo; Assigned to Arm(s): glimepiride 1-4 mg QD | Intervention Type: DRUG; Name: glimepiride placebo; Assigned to Arm(s): linagliptin
B: Arm Label: Dapagliflozin+metformin; Type: ACTIVE_COMPARATOR; Interventions: Drug: Dapagliflozin, Drug: Placebo for saxagliptin, Drug: Placebo for glimepiride | Arm Label: Dapagliflozin+saxagliptin+metformin; Type: ACTIVE_COMPARATOR; Interventions: Drug: Dapagliflozin, Drug: Saxagliptin, Drug: Placebo for glimepiride | Arm Label: Glimepiride+metformin; Type: ACTIVE_COMPARATOR; Interventions: Drug: Glimepiride, Drug: Placebo for dapagliflozin, Drug: Placebo for saxagliptin | Intervention Type: DRUG; Name: Dapagliflozin; Assigned to Arm(s): Dapagliflozin+metformin, Dapagliflozin+saxagliptin+metformin | Intervention Type: DRUG; Name: Saxagliptin; Assigned to Arm(s): Dapagliflozin+saxagliptin+metformin | Intervention Type: DRUG; Name: Glimepiride; Assigned to Arm(s): Glimepiride+metformin | Intervention Type: DRUG; Name: Placebo for dapagliflozin; Assigned to Arm(s): Glimepiride+metformin | Intervention Type: DRUG; Name: Placebo for saxagliptin; Assigned to Arm(s): Dapagliflozin+metformin, Glimepiride+metformin | Intervention Type: DRUG; Name: Placebo for glimepiride; Assigned to Arm(s): Dapagliflozin+metformin, Dapagliflozin+saxagliptin+metformin
C: Arm Label: Metformin + Alogliptin 12.5 mg; Type: EXPERIMENTAL; Interventions: Drug: Alogliptin, Drug: Metformin | Arm Label: Metformin + Alogliptin 25 mg; Type: EXPERIMENTAL; Interventions: Drug: Alogliptin, Drug: Metformin | Arm Label: Metformin + Glipizide; Type: ACTIVE_COMPARATOR; Interventions: Drug: Metformin, Drug: Glipizide | Intervention Type: DRUG; Name: Alogliptin; Assigned to Arm(s): Metformin + Alogliptin 12.5 mg, Metformin + Alogliptin 25 mg | Intervention Type: DRUG; Name: Metformin; Assigned to Arm(s): Metformin + Alogliptin 12.5 mg, Metformin + Alogliptin 25 mg, Metformin + Glipizide | Intervention Type: DRUG; Name: Glipizide; Assigned to Arm(s): Metformin + Glipizide
D: Arm Label: Saxagliptin; Type: EXPERIMENTAL; Interventions: Drug: Metformin, Drug: Saxagliptin | Arm Label: Glipizide; Type: EXPERIMENTAL; Interventions: Drug: Metformin, Drug: Sulphonylurea | Intervention Type: DRUG; Name: Metformin; Assigned to Arm(s): Glipizide, Saxagliptin | Intervention Type: DRUG; Name: Sulphonylurea; Assigned to Arm(s): Glipizide | Intervention Type: DRUG; Name: Saxagliptin; Assigned to Arm(s): Saxagliptin

Answer: D